Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01287845 · ClinicalTrials.gov registry record · Phase 1

PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers

A Phase 1 study of Diagnostic Imaging, sponsored by Life Molecular Imaging.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
2
Study locations

NCT01287845: Completed Phase 1 study of Diagnostic Imaging, sponsored by Life Molecular Imaging.

NCT01287845 is a Phase 1 study of Diagnostic Imaging that has completed, run by Life Molecular Imaging. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01287845, a Phase 1 study of Diagnostic Imaging, has completed, sponsored by Life Molecular Imaging.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
2
Study locations

Study Summary

PET/CT imaging study for evaluation of safety and tolerability and diagnostic performance of BAY1075553 in patients with prostate cancer and in healthy volunteers

Conditions Studied

Interventions

  • DRUG BAY1075553

Study Locations (2)

Michigan

  • - Ann Arbor

Other

  • - Linz

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2011-02
Est. Completion 2011-11
Phase Phase 1
Life Molecular Imaging

4 total trials

What the finished NCT01287845 record still lists

NCT01287845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Diagnostic Imaging appearing as the primary indexed condition, and to 1 intervention - of which BAY1075553 is the first listed.

NCT01287845 reports a single indexed study location in Michigan, Other.

Frequently Asked Questions

What is clinical trial NCT01287845 about?

NCT01287845 is a clinical study titled "PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers". PET/CT imaging study for evaluation of safety and tolerability and diagnostic performance of BAY1075553 in patients with prostate cancer and in healthy volunteers

What is the current status of trial NCT01287845?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-02. Estimated completion is 2011-11.

What conditions does trial NCT01287845 study?

This clinical trial studies the following conditions: Diagnostic Imaging.

What interventions are being tested in trial NCT01287845?

The interventions under investigation include: BAY1075553 (DRUG).

Who is sponsoring clinical trial NCT01287845?

This trial is sponsored by Life Molecular Imaging, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01287845 being conducted?

This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diagnostic Imaging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01287845's enrollment target sits among peer trials

14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01287845, the US trial registry maintained by the National Library of Medicine. NCT01287845 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.